{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.05986"}, {"@name": "filename", "#text": "10471_Giselia%20dos%20Santos%20Santana%20Estudo...2004.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "UFBA\nUNIVERSIDADE FEDERAL DA BAHIA FACULDADE DE MEDICINA FUNDA\u00c7\u00c3O OSWALDO CRUZ CENTRO DE PESQUISAS GON\u00c7ALO MONIZ\nCurso de P\u00f3s-Gradua\u00e7\u00e3o em Patologia\nDISSERTA\u00c7\u00c3O DE MESTRADO\nESTUDO DA ASSOCIA\u00c7\u00c3O ENTRE nIvEIS PLASM\u00c1TICOS DE ZINCO E RESPOSTA IMUNE NA LEISHMANIOSE HUMANA\nGISELIA DOS SANTOS SANTANA\nSalvador - .Bahia - Brasil 2004\n\u00a161.847.532\nUNIVERSIDADE FEDERAL DA BAHIA FACULDADE DE MEDICINA FUNDA\u00c7\u00c3O OSWALDO CRUZ CENTRO DE PESQUISA GON\u00c7ALO MONIZ\nCurso de P\u00f3s-Gradua\u00e7\u00e3o em Patologia\nDISSERTA\u00c7\u00c3O DE MESTRADO\nESTUDO DA ASSOCIA\u00c7\u00c3O ENTRE N\u00cdVEIS PLASM\u00c1TICOS DE ZINCO E RESPOSTA IMUNE NA LEISHMANIOSE HUMANA\nGIS\u00c9LIA DOS SANTOS SANTANA\nOrientador: Johan Van Weyenbergh\nDisserta\u00e7\u00e3o apresentada para obten\u00e7\u00e3o de grau de Mestre em Patologia, \u00e1rea de concentra\u00e7\u00e3o em Patologia Experimental\nSalvador-Bahia\tj\nFicha Catalogr\u00e1fica elaborada pela Biblioteca do CPqGM /FIOCRUZ Salvador - Bahia.\nSantana, Gis\u00e9lia dos Santos\nS232e Estudo da associa\u00e7\u00e3o entre os n\u00edveis plasm\u00e1ticos de zinco e a resposta imune na Leishmaniose humana [manuscrito], / Gis\u00e9lia dos Santos Santana. - 2004.\n26 f. : il. ; 30 cm.\nDisserta\u00e7\u00e3o (Mestrado em Patologia Experimental) - Universidade Federal da Bahia, Faculdade de Medicina.\nCentro de Pesquisas Gon\u00e7alo Moniz, 2004.\nOrientador: Prof. Dr. Johan Van Weyenbergh. Laborat\u00f3rio de Imuno Regula\u00e7\u00e3o e Microbiolog\u00eda.\n1. Leishmaniose. 2. Zinco. 3. Cobre. 4. Imunidade Celular. 5. Imunidade humoral. I. T\u00edtulo.\nCDU\n616.993.161:661.847.532\nESTUDO DA ASSOCIA\u00c7\u00c3O ENTRE N\u00cdVEIS PLASM\u00c1TICOS DE ZINCO E RESPOSTA IMUNE NA LEISHMANIOSE HUMANA.\nGIS\u00c9LIA DOS SANTOS SANTANA\nFOLHA DE APROVA\u00c7\u00c3O\nCOMISS\u00c3O EXAMINADORA\n>* Dr. Roque Pacheco de Almeida Professor Adjunto FAMED - UFBA\nDr. Mitermayer Gal v\u00e3o dos Reis / Pesquisador Titular /\u25a0 CPqGM - FIOCRUZ z\nDr. Johan Van Weyenbergh Pesquisador Associado CPqGM - FIOCRUZ\nAGRADECIMENTOS\nA Deus, raz\u00e3o de minha exist\u00eancia\nA minha m\u00e3e, pelo seu amor, carinho, apoio e por tudo que me ensinou\nA Johan, pela sua orienta\u00e7\u00e3o, disponibilidade e incentivo\nAo Dr. Manoel Barral-Netto, por ter me concedido a oportunidade de iniciar minha trajet\u00f3ria na pesquisa, junto aos pesquisadores do LIMI\nAos membros da banca, Prof. Roque Pacheco Almeida, Prof. Mitermayer Galv\u00e3o dos Reis e Prof Jackson Costa, pela contribui\u00e7\u00e3o na vers\u00e3o final da disserta\u00e7\u00e3o\n\u00c0 Prof. Maria das Gra\u00e7as Korner e ao Prof An\u00edbal Freitas Santos Jr. do Instituto de Qu\u00edmica/UFBA pela realiza\u00e7\u00e3o das dosagens dos metais\nA equipe cl\u00ednica; Dra. Aldina Barrai, Dr. Argemiro d Oliveira Jr. , Dr . Edgar Marcelino Carvalho, Dra. Arlene Caldas, Dr. Jackson Costa e Dr. Carlos Henrique Costa\nAos pacientes e volunt\u00e1rios que participaram deste estudo\nAos amigos do laborat\u00f3rio ( LIMI e LIP), pelo incentivo constante e solidariedade\nAos colegas do mestrado, pelos momentos agrad\u00e1veis de aprendizado e amizade\nA Jorge Tolentino, Silvia, Cl\u00e1udio, Cec\u00edlia, Dirceu , Sebasti\u00e3o, Jo\u00e3o Paulo, Vera, Jos\u00e9 Carlos e Maria Lizete pela colabora\u00e7\u00e3o no desenvolvimento do trabalho\nA Aline, Cristiano, Daniele, Adriana, George, Gilvaneia, Lourdes, Maria da Pirifica\u00e7\u00e3o e Ricardo pelo trabalho em equipe\n\u00c0 Theolis, pela conviv\u00eancia e incentivo\n\u00c0 minha amiga Amanda Alexandra Guimar\u00e3es Costa\nAos meus queridos professores do Instituto de Biologia/UFBA, pela importante contribui\u00e7\u00e3o na minha forma\u00e7\u00e3o acad\u00eamica\nA Ros\u00e1lia Meire e Rosecarla, pelo carinho e aten\u00e7\u00e3o constante\nAo curso de P\u00f3s-gradua\u00e7\u00e3o e aos professores, pela dedica\u00e7\u00e3o\nAs bibliotec\u00e1rias Ana Maria Piscina e Adelvane, pela ajuda na obten\u00e7\u00e3o e organiza\u00e7\u00e3o das refer\u00eancias bibliogr\u00e1ficas\nAos setores de comunica\u00e7\u00e3o visual e inform\u00e1tica, pelo apoio na elabora\u00e7\u00e3o dos recursos visuais necess\u00e1rios para o desenvolvimento do trabalho.\nAo Centro de Pesquisa Gon\u00e7alo Moniz, pela disponibilidade de espa\u00e7o fisico, pessoal e recursos que possibilitaram a realiza\u00e7\u00e3o deste trabalho.\nAo PIBIC/UFBA pelo incentivo na Inicia\u00e7\u00e3o cientifica\nA CAPES e CNPq pelo apoio financeiro.\nSUM\u00c1RIO\nLISTA DE ABREVIATURAS\nRESUMO\nABSTRACT\nINTRODU\u00c7\u00c3O\t1\n1.\tConsidera\u00e7\u00f5es gerais\t1\n2.\tDesnutri\u00e7\u00e3o e doen\u00e7as carenciais\t6\n3.\tIntera\u00e7\u00e3o resposta imune e nutri\u00e7\u00e3o\t8\nHIP\u00d3TESE\t10\nOBJETIVOS\t10\nJUSTIFICATIVA\t12\nMANUSCRITO\nDISCUSS\u00c3O E PERSPECTIVAS\t13\nCONCLUS\u00d5ES\t16\nBIBLIOGRAFIA\t17\nANEXOS\n23\nLISTA DE ABREVIATURAS\nLCL\tLeishmaniose cut\u00e2nea localizada\nLM\tLeishmaniose Mucosa\nLV\tLeishmaniose Visceral\nLCD\tLeishmaniose cut\u00e2nea difusa\nTh\tC\u00e9lulas T auxiliar\nIFN-y\tInterferon Gama\nIL\tInterleucina\nINF- a\tFator de Necrose Tumoral alfa\nAIDS\tS\u00edndrome da Imunodefici\u00eancia Adquirida\nnk\tNatural Killer\nCu\tCobre\nZn\tZinco\nOMS\tOrganiza\u00e7\u00e3o Mundial de Sa\u00fade\nRESUMO\nESTUDO DA ASSOCIA\u00c7\u00c3O ENTRE N\u00cdVEIS PLASM\u00c1TICOS DE ZINCO E RESPOSTA\nIMUNE NA LEISHMANIOSE HUMANA. GIS\u00c9LIA DOS SANTOS SANTANA.\nA leishmaniose mucosa, cut\u00e2nea localizada, e visceral, s\u00e3o caracterizadas por apresentar uma resposta imune celular exacerbada , intermedi\u00e1ria e ineficiente, respectivamente. Foi investigado os niveis de cobre e zinco em diferentes formas cl\u00ednicas da leishmaniose e a correla\u00e7\u00e3o da resposta imune humoral e/ou celular contra o parasita. Foi coletado sangue de 32 pacientes com leishmaniose cut\u00e2nea localizada (LCL), mucosa (LM) ou visceral (LV), bem como de 25 controles urbanos e de \u00e1rea end\u00eamica. Os niveis plasm\u00e1ticos de Cu e Zn foram quantificados por espectrofotometria de absor\u00e7\u00e3o at\u00f4mica. A resposta imune celular e humoral wt\u00e0-Leishmania foram avaliadas por quantifica\u00e7\u00e3o de IgG plasm\u00e1tica espec\u00edfica, linfoprolifera\u00e7\u00e3o e produ\u00e7\u00e3o de citocinas, respectivamente. Uma diminui\u00e7\u00e3o significante de Zn no plasma foi observada em todos os tr\u00eas grupos de pacientes , quando comparados com controles, mas apenas nos pacientes com LV (7/10) e LM (1/7) foi observada uma defici\u00eancia aguda de Zn. Os n\u00edveis plasm\u00e1ticos de Cu estavam aumentado nos pacientes com LCL e LV, mas n\u00e3o em LM, e correlacionaram-se significantemente com IgG an\u00fa-Leishmania. A raz\u00e3o Cu/Zn foi elevada em pacientes com defici\u00eancia na resposta imune celular (LV<<LCL<LM) e exacerbada resposta imune humoral (LV>LCL>ML). A poss\u00edvel associa\u00e7\u00e3o de defici\u00eancia de Zn com dados cl\u00ednicos foi avaliada em estudo prospectivo de 12 pacientes com LV, nos quais os n\u00edveis de Zn eram preditivos para a evolu\u00e7\u00e3o do tamanho de ba\u00e7o. Conclu\u00edmos que defici\u00eancia de Zn em LV e LM indica a possibilidade da administra\u00e7\u00e3o terap\u00eautica de Zn nessas formas severas da leishmaniose, e que o aumento da raz\u00e3o Cu/Zn pode ser um marcador da disfun\u00e7\u00e3o imune na leishmaniose.\nPalavras-chave: leishmaniose, zinco, cobre, imunidade celular, imunidade humoral\nABSTRACT\nSTUDY OF THE ASSOCIATION BETWEEN PLASMA ZINC LEVELS AND IMMUNE RESPONSE IN HUMAN LEISHMANIASIS. GISELIA DOS SANTOS SANTANA.\nMucosal (ML), localized cutaneous (LCL) and visceral leishmaniasis (VL) are characterized by exacerbated, intermediate and inefficient cellular immune response, respectively. We investigated if zinc and copper levels differ in distinct clinical forms of leishmaniasis, and if they correlate to humoral and/or cellular immune response towards the parasite. Blood was collected from 32 patients with either localized cutaneous (LCL), mucosal (ML) or visceral (VL) leishmaniasis, as well as from 25 controls from endemic and non-endemic areas. Plasma levels of Cu and Zn were quantified by atomic absorption spectrophotometry. Ant\\-Leishmania humoral and cellular immune response were evaluated by quantifying specific plasma IgG, lymphoproliferation and cytokine production, respectively. A significant decrease in plasma Zn was observed in all three patient groups, as compared to controls, but only VL (7/10) and ML (1/7) patients displayed overt Zn deficiency. Plasma Cu was increased in LCL and VL but not in ML, and was strongly correlated to anti-Leishmania IgG. Cu/Zn ratios were highest in patients with deficient cellular (VL<<LCL<ML) and exacerbated humoral (VL>LCL>ML) immune response. A possible association between Zn deficiency and clinical findings was investigated in a prospective study of 12 VL patients, for whom Zn levels were found to be predictive for spleen size evolution. In conclusion, Zn deficiency in VL and ML indicate possible therapeutic administration of Zn in these severe forms of leishmaniasis and increased Cu/Zn ratio can be a useful marker for immune dysfunction in leishmaniasis.\nKey Words: leishmaniasis, zinc, copper, cellular immunity, humoral immunity\nINTRODU\u00c7\u00c3O\n1.\tFundamenta\u00e7\u00e3o Te\u00f3rica\nDenominam-se leishmanioses ao conjunto de s\u00edndromes cl\u00ednicas causadas por protozo\u00e1rios do g\u00eanero Leishmania, transmitidas pela picada de inseto do g\u00eanero Phlebotomus (Velho Mundo) ou Lutzomya (Novo Mundo) (PEARSON et al, 1983), Encontram-se entre as seis doen\u00e7as respons\u00e1veis pelas grandes endemias no mundo, ocupando o segundo lugar em import\u00e2ncia m\u00e9dica entre as doen\u00e7as causadas por protozo\u00e1rios (OMS, 1990). Estimativas da Organiza\u00e7\u00e3o Mundial da Sa\u00fade (OMS) mostram em todo o mundo, um total de 350 milh\u00f5es de indiv\u00edduos expostos ao risco de contrair a infec\u00e7\u00e3o por Leishmania, com incid\u00eancia anual de 12 milh\u00f5es de casos (WHO, 1990; ABRAMSON, et al. 1995).\nCaracter\u00edsticas epidemiol\u00f3gicas distinguem dois padr\u00f5es da doen\u00e7a no Brasil;\n1)\tsurtos epid\u00eamicos associados \u00e0 derrubada de matas, com a finalidade de constru\u00e7\u00e3o de estradas e instala\u00e7\u00e3o de novos povoados e a explora\u00e7\u00e3o desordenada da floresta para a extra\u00e7\u00e3o de madeira, utiliza\u00e7\u00e3o do solo na agricultura, pecu\u00e1ria, entre outras, caracterizando a doen\u00e7a como uma zoonose de animais silvestres como o gamb\u00e1 e o rato do mato, podendo atingir o homem quando esse mantiver contato com os focos zoon\u00f3ticos;\n2)\tleishmaniose em regi\u00f5es de coloniza\u00e7\u00e3o antiga, est\u00e1 relacionada ao processo migrat\u00f3rio, ocupa\u00e7\u00e3o de encostas e aglomerados semiurbanizados na periferia de centros urbanos, n\u00e3o associados \u00e1 derrubada das matas. Neste padr\u00e3o outros animais est\u00e3o envolvidos na\ntransmiss\u00e3o da doen\u00e7a, servindo como reservat\u00f3rios; c\u00e3es, eq\u00fcinos e roedores. (MS-FNS, 1998 &amp;\nAs leishmanioses podem ocorrer na forma tegumentar (LT) ou visceral (LV). A tegumentar caracteriza-se por apresentar diferentes manifesta\u00e7\u00f5es clinicas como a leishmaniose cut\u00e2nea (LC), que apresenta les\u00f5es que regridem espontaneamente ou respondem bem ao tratamento; a leishmaniose mucosa (LM), resultante da dissemina\u00e7\u00e3o do parasita de les\u00f5es prim\u00e1rias para regi\u00f5es de mucosa e a leishmaniose cut\u00e2nea difusa (LCD), que produz les\u00f5es disseminadas que n\u00e3o regridem espontaneamente e s\u00e3o refrat\u00e1rias ao tratamento. A forma visceral \u00e9 uma manifesta\u00e7\u00e3o sist\u00eamica da doen\u00e7a, que envolve progress\u00e3o difusa do parasita direto para ba\u00e7o, figado e medula \u00f3ssea. \u00c9 tamb\u00e9m conhecida por calazar, apresenta maior mortalidade em indiv\u00edduos sem tratamento (BITTENCOLRtT e BARRAL-NETTO, 1995).\nNo Brasil, a distribui\u00e7\u00e3o geogr\u00e1fica da LT \u00e9 ampla e apenas o estado do Rio Grande do Sul n\u00e3o \u00e9 atingido. A regi\u00e3o Norte representou 36,5%, a Nordeste 38,9%, Centro-Oeste 15,1%, Sudeste 7,3% e a regi\u00e3o Sul 2,2% dos casos de LT notificados em 1995. Al\u00e9m da melhoria do fluxo de informa\u00e7\u00e3o que aumentou a notifica\u00e7\u00e3o dos casos de LT, houve expans\u00e3o tanto em n\u00famero de casos quanto de \u00e1reas geogr\u00e1ficas. Entre os anos de 1985-1999, foram notificados no pais 388.155 casos aut\u00f3ctones de LT, sendo o Norte a regi\u00e3o com o maior coeficiente de detec\u00e7\u00e3o (CD). (FNS-MS, 1998 &amp; FNS-MS, 2000). Entre 1985-2002, foram notificados 34.884 casos de LV. Os estados mais afetados foram Bahia, Ce\u00e1ra, Maranh\u00e3o e Piaui (FNS-MS, 2002).\nAs leishmanias envolvidas na transmiss\u00e3o da LT no Brasil s\u00e3o: Leishmania amazonensis, Leishmania guayanensis. Leishmania braziliensis, cujos principais vetores s\u00e3o esp\u00e9cies de fiebotomineos do g\u00eanero Lutzomya. A Leishmania amazonensis, tem como seus principais vetores os Lutzomya flaviscuetella\u00eda, Lutzomya reducta e Lutzomya olmeca, encontrados principalmente\nnos estados do Amazonas e Rond\u00f4nia, podendo ocorrer ainda em outras regi\u00f5es do pais, por\u00e9m, com baixa freq\u00fc\u00eancia. A L amazonensis \u00e9 respons\u00e1vel pela forma LCL, podendo alguns indiv\u00edduos desenvolverem a forma LCD, (VEXENAT et al, 1986; FNS-MA, 1991; 2000; BARRAL et al, 1991; COSTA et al, 1998). A L. guayanensis apresenta como seus principais vetores Lutzomyia anduzei, Lutzomya whitmani e Lutzomya umbratilis, sua ocorr\u00eancia foi relatada no norte da Bacia Amaz\u00f4nica nos estados do Amap\u00e1, Roraima e Par\u00e1. Individuos, quando infectados por essa esp\u00e9cie desenvolvem les\u00f5es \u00fanicas ou m\u00faltiplas (LAINSON et al, 1981; FNS-MS, 2000). A L.braziliensis, encontra-se amplamente distribu\u00edda do sul do Par\u00e1 ao Nordeste brasileiro, atingindo tamb\u00e9m o centro sul do pais e algumas \u00e1reas da Amaz\u00f4nia Oriental, seus principais vetores s\u00e3o Lutzomya. interm\u00e9dia, Lutzomya migonei e Lutzomy whitmani. Individuos quando infectados por essa esp\u00e9cie de Leishmania, desenvolvem a LCL, cuja principal complica\u00e7\u00e3o \u00e9 a evolu\u00e7\u00e3o para LM (VEXANET et al., 1986; SILVEIRA, et al, 1991; PASSOS et al, 1993; QUEIROZ etal, 1994; FNS-MS, 2000).\nNa LV, as leishmanias envolvidas s\u00e3o; L. chagasi, L.infantum e L. donovani, sendo no Brasil a L. chagasi respons\u00e1vel pela doen\u00e7a, a qual apresenta aspectos geogr\u00e1ficos, clim\u00e1ticos e sociais diferenciados em fun\u00e7\u00e3o da sua ampla distribui\u00e7\u00e3o geogr\u00e1fica, envolvendo as regi\u00f5es Norte, Nordeste, Centro-Oeste e Sudeste, sendo o Nordeste respons\u00e1vel por 90% dos casos em nosso pais durante a d\u00e9cada de 90, principalmente nos estados da Bahia, Cear\u00e1, Maranh\u00e3o e Piau\u00ed. (MS-FNS, 1998 &amp; 2000).\nEm rela\u00e7\u00e3o ao ciclo de transmiss\u00e3o da LV, observa-se que os reservat\u00f3rios silvestres da L. chagasi s\u00e3o as raposas (Cerdocion thous e Dusycion vetulus) e marsupiais (Didelphis sp), e no ambiente dom\u00e9stico o c\u00e3o {Canis familiares)). O Lutzomya longipalpis \u00e9 a esp\u00e9cie mais conhecida\n3\ncomo transmissora da L.chagasi, tendo sido recentemente incriminado o Lutzomya.cruzi como vetor no estado de Mato Grosso do Sul (LAINSON &amp; SHAW, 1987; MS. 2003).\nAs manifesta\u00e7\u00f5es cl\u00ednicas da LV podem ser agrupadas em tr\u00eas formas:\n1\t- assintom\u00e1tica caracteriza-se por positividade no exame sorol\u00f3gico para Leishmania, sem nenhuma manifesta\u00e7\u00e3o cl\u00ednica;\n2\t- oligossintom\u00e1tica, encontrada na \u00e1rea end\u00eamica, apresenta exame sorol\u00f3gico positivo e presen\u00e7a de sinais e sintomas discretos, como febre, hepatomegalia e/ ou esplenomegalia de pequeno grau;\n3\t- cl\u00ednicamente manifesta (aguda/cl\u00e1ssica), caracteriza-se por hepatoesplenomegalia volumosa, febre, pancitopenia, comprometimento do estado geral. A desnutri\u00e7\u00e3o est\u00e1 presente, com acentuada hipoalbuminemia e hipergamaglobulinemia (SILVA, 1957; BADAR\u00d3 et ai, 1986). A prefer\u00eancia por crian\u00e7as menores de cinco anos de idade, \u00e9 a principal caracter\u00edstica da forma neo-tropical da LV e se relaciona, provavelmente, com o comprometimento da resposta imune, pr\u00f3pria dos estados de desnutri\u00e7\u00e3o que geralmente acometem as crian\u00e7as dessa faixa et\u00e1ria em algumas regi\u00f5es dos continentes americano, africano e asi\u00e1tico, funcionando como um fator predisponente para a doen\u00e7a (CAMPOS Jr., 1995; SILVA, et al, 1997).\nA Leishmania apresenta duas formas distintas em seu ciclo de vida, a promastigota e amastigota. A promastigota \u00e9 afilada, m\u00f3vel, apresenta flagelo e atrav\u00e9s da picada do inseto vetor \u00e9 transmitida ao hospedeiro vertebrado. Na pele do hospedeiro vertebrado, promastigotas s\u00e3o internalizados por fag\u00f3citos mononucleares, perdem (internalizam) o flagelo e diferenciam-se em amastigotas. As amastigotas apresentam uma forma arredondada, m\u00f3vel e com flagelo interno. A progress\u00e3o da infec\u00e7\u00e3o ocorre quando h\u00e1 ruptura de macr\u00f3fagos, resultando na libera\u00e7\u00e3o de\n4\namastigotas no meio extracelular e infec\u00e7\u00e3o subseq\u00fcente de c\u00e9lulas adjacentes. O ciclo de vida da Leishmania continua quando um outro inseto se alimenta do sangue de um hospedeiro infectado e ingere macr\u00f3fagos da pele contendo amastigotas. No intestino do inseto, as amastigotas s\u00e3o liberadas de macr\u00f3fagos infectados e diferenciam-se em promastigotas, aproximadamente 12-18 horas ap\u00f3s ingest\u00e3o. A seq\u00fc\u00eancia de acontecimentos, a partir do momento da picada do inseto vetor at\u00e9 o aparecimento de sinais e sintomas da doen\u00e7a, depende da esp\u00e9cie de Leishmania envolvida e de fatores intr\u00ednsecos do hospedeiro, incluindo, caracter\u00edsticas gen\u00e9ticas e resposta imunol\u00f3gica. A express\u00e3o cl\u00ednica da doen\u00e7a resulta, da intera\u00e7\u00e3o do parasita com o hospedeiro vertebrado nas v\u00e1rias fases da infec\u00e7\u00e3o (LAINSON et al, 1987; BITTENCOURT &amp; BARRAL-NETTO, 1995).\nO conhecimento da imunidade nas leishmanioses tem sido facilitado pelo uso de linhagens de camundongos que s\u00e3o suscept\u00edveis \u00e0 esp\u00e9cie L. major. Embora tanto camundongos C57BL/6 quanto BALB/C sejam suscept\u00edveis \u00e0 infec\u00e7\u00e3o por L. major, camundongos C57BL/6 s\u00e3o usados como modelo exper\u00edmental de linhagens resistentes pelo fato de resolverem a infec\u00e7\u00e3o resultando na cura, enquanto camundongos BALB/C falham no controle local da replica\u00e7\u00e3o do parasita, levando a progress\u00e3o da doen\u00e7a e morte desses animais. Esses modelos foram importantes para a defini\u00e7\u00e3o dos dois tipos de resposta imune, onde sub-popula\u00e7\u00f5es diferentes Thl e Th2 participam dessa resposta imune levando a cura ou \u00e0 progress\u00e3o da doen\u00e7a (SCOTT et al, 1989; HEINZEL et al., 1989). Nessa dicotomia, v\u00ea-se que a susceptibilidade de camundongos BALB/C \u00e9 dependente da produ\u00e7\u00e3o de IL-4 no in\u00edcio da infec\u00e7\u00e3o, enquanto, o controle da infec\u00e7\u00e3o e resist\u00eancia \u00e0 re-infec\u00e7\u00e3o observada em camundongos C57BL/6 \u00e9 dependente de IFN-y. Logo dois perfis distintos de c\u00e9lulas T CD4+ foram identificados. Uma sub-popula\u00e7\u00e3o que apresenta fenotipo Thl que\n5\nproduz IL-2, TNT-a e principalmente IFN-y e outra sub-popula\u00e7\u00e3o com fenotipo Th2 que produz citocinas como IL-5, IL-10 e principalmente IL-4 que conferem o fenotipo de susceptibilidade e progress\u00e3o da doen\u00e7a. Alguns estudos demonstraram que c\u00e9lulas Thl s\u00e3o requeridas para ativar imunidade dependente de fagocitose, consistentes com dados vistos na leishmaniose, uma infec\u00e7\u00e3o intracelular de macr\u00f3fagos. Em contraste, c\u00e9lulas Th2 s\u00e3o requeridas por ativar imunidade independente de fagocitose, sendo seu papel ainda implicado em doen\u00e7as al\u00e9rgicas e infec\u00e7\u00f5es helm\u00ednticas. (FREDERICK e\u00ed al, 1989; LOCKSLEY e\u00ed al., 1999).\nAl\u00e9m da infec\u00e7\u00e3o por parasitas intracelulares, outro fator bem estudado de falha na resposta imune \u00e9 o estado nutricional. Alguns estudos t\u00eam demonstrado que a condi\u00e7\u00e3o nutricional \u00e9 um determinante cr\u00edtico da resposta imune, e a desnutri\u00e7\u00e3o mostra-se como uma das causas de imunodefici\u00eancia por todo mundo (BADARO et al, 1986; EVANS et al., 1992: DYE &amp; WILLIAMS, 1993; CHANDRA, 1997).\n2.\tDesnutri\u00e7\u00e3o e Doen\u00e7as Carenciais\nA nutri\u00e7\u00e3o estuda os alimentos, micro e macro nutrientes e o pr\u00f3prio ato de se alimentar. Um dos grandes problemas na determina\u00e7\u00e3o do estado nutricional \u00e9 classificar o tipo de desnutri\u00e7\u00e3o, uma vez que esta tem causas diversas, al\u00e9m disso, os padr\u00f5es utilizados para classifica\u00e7\u00e3o do estado nutricional, baseiam-se em \u00edndice de refer\u00eancias mundial, o que pode n\u00e3o estar refletindo a realidade local, devido \u00e1s diferen\u00e7as culturais (OMS, 1999).\n6\nA desnutri\u00e7\u00e3o grave pode apresentar-se como marasmo (defici\u00eancia cal\u00f3rica) ou kwashiokor (defici\u00eancia prot\u00e9ica). A obten\u00e7\u00e3o e a manuten\u00e7\u00e3o de um peso apropriado para a altura, sexo, idade e a atividade f\u00edsica durante o per\u00edodo de vida de um individuo \u00e9 importante para evitar diversos problemas de sa\u00fade, e tamb\u00e9m para o desenvolvimento cognitivo (DILLINGHAM &amp; GUERRANT, 2004). Desnutri\u00e7\u00e3o \u00e9 comumente associada com infec\u00e7\u00f5es cr\u00f4nicas, doen\u00e7as endocrinas e auto-imunes, c\u00e2ncer e AIDS (VICTORA et al, 1986).\nO resultado da infec\u00e7\u00e3o por Leishmania \u00e9 provavelmente dependente de m\u00faltiplos fatores. Dois estudos realizados no Nordeste do Brasil sugerem que a desnutri\u00e7\u00e3o \u00e9 um deles. A primeira evid\u00eancia que demonstrou que a desnutri\u00e7\u00e3o est\u00e1 associada com o desenvolvimento da LV, resultou dos estudos de HARRISON et al. (1983), em que o estado nutricional de crian\u00e7as com LV da mesma idade e sexo e que residem na mesma casa, foi comparado com crian\u00e7as controles randomicamente selecionadas da vizinhan\u00e7a de algumas classes sociais, usando medidas antropom\u00e9tricas. O estudo foi conduzido em uma \u00e1rea de alta endemicidade no estado do Cear\u00e1 -Brasil, onde aproximadamente 80% dos casos de LV ocorrem em crian\u00e7as menores de 10 anos de idade. Os dados deste estudo sugerem uma associa\u00e7\u00e3o entre desnutri\u00e7\u00e3o e desenvolvimento de LV grave, utilizando no per\u00edodo pr\u00e9-infec\u00e7\u00e3o a \u00e1rea de gordura de pacientes que residem na mesma casa, como indicativo do estado nutricional. Um outro estudo na Bahia demonstrou que desnutri\u00e7\u00e3o est\u00e1 associada com a progress\u00e3o da infec\u00e7\u00e3o por LV grave, o risco relativo de desenvolvimento de LV severa foi de 8.7 vezes maior entre crian\u00e7as com desnutri\u00e7\u00e3o severa a moderada que entre crian\u00e7as com estado nutricional normal ou que tem apenas desnutri\u00e7\u00e3o leve (BADAR\u00d3 et al, 1988). Esses estudos n\u00e3o estabeleceram uma rela\u00e7\u00e3o causai entre desnutri\u00e7\u00e3o e o desenvolvimento de LV, contudo essas s\u00e3o consideradas evidencias por indicar que desnutri\u00e7\u00e3o pode resultar em imunodefici\u00eancia em humanos.\n7\nDesnutri\u00e7\u00e3o prot\u00e9ico-cal\u00f3rica est\u00e1 associada com falha significante da resposta imune mediada por c\u00e9lula: na fun\u00e7\u00e3o fagocit\u00e1ria, no sistema de complemento, e na produ\u00e7\u00e3o de citocinas. Defici\u00eancia de um \u00fanico nutriente como: zinco, sel\u00eanio, ferro, cobre, vitaminas A, C, E e B6 ou \u00e1cido f\u00f3lico tem resultado em altera\u00e7\u00f5es da resposta imune. Por exemplo, a vitamina A \u00e9 considerada anti-infecciosa e sua defici\u00eancia est\u00e1 associada a um maior risco de infec\u00e7\u00f5es graves, como demonstrado em estudo realizado em crian\u00e7as com LV onde o n\u00edvel s\u00e9rico de vitamina A encontrava-se diminu\u00eddo quando comparado com controles de \u00e1rea end\u00eamica (CHANDRA, 1997; LUZ et al., 2001; PRASAD 2002).\n3.\tIntera\u00e7\u00e3o Resposta Imune e Nutri\u00e7\u00e3o\nDe um modo geral, d\u00e9ficits imunol\u00f3gicos correlacionam-se bem com mudan\u00e7as observadas no tamanho e peso do timo e linfonodos vistas em crian\u00e7as e adultos com desnutri\u00e7\u00e3o, tais altera\u00e7\u00f5es ocorrem devido a diminui\u00e7\u00e3o do n\u00famero de c\u00e9lulas imune (CHANDRA, 1997 &amp; RJNK, 2000).\nNa imunidade inata, defeitos na ativa\u00e7\u00e3o do complemento e das \u00ed\u00fcn\u00e7\u00f5es de polimorfonucleares t\u00eam tamb\u00e9m sido relatados, al\u00e9m da atividade de c\u00e9lulas NK encontrar-se diminu\u00edda em crian\u00e7as com kwashiokor e marasmo.\nNa imunidade adquirida, a resposta imune celular parece ser o componente da imunidade mais freq\u00fcentemente afetado. Anormalidade na hipersensibilidade cut\u00e2nea tardia para uma variedade de ant\u00edgenos dependentes de c\u00e9lulas T tem sido demonstrado em crian\u00e7as desnutridas. A atividade t\u00edmica tamb\u00e9m encontra-se comprometida pela redu\u00e7\u00e3o da atividade da timulina, que \u00e9 o\n8\nhorm\u00f4nio t\u00edmico respons\u00e1vel pela matura\u00e7\u00e3o e ativa\u00e7\u00e3o de c\u00e9lulas T. A desnutri\u00e7\u00e3o provavelmente afeta a expans\u00e3o da prote\u00e7\u00e3o potencial antigeno-especifico de sub-popula\u00e7\u00e3o de c\u00e9lulas T produtoras de interferon-gama, que s\u00e3o mediadores diretos da morte de pat\u00f3genos intracelulares (CHANDRA, 1997, RINK &amp; KIRCHNER 2000).\nTanto a desnutri\u00e7\u00e3o, quanto \u00e0 defici\u00eancia de micro-nutrientes espec\u00edficos, parecem interferir na resposta imune sendo, portanto, um fator importante na susceptibilidade e progress\u00e3o de doen\u00e7as infecciosas.\n9\nHIP\u00d3TESE\nZimc\u00f3 influencia n rcspostn imumc mn lcishmnmiosc humnmn.\nOBJETIVOS\nObjetivo geral:\nEstudar a poss\u00edvel associa\u00e7\u00e3o entre os n\u00edveis plasm\u00e1ticos de zinco e a resposta imune na leishmaniose humana.\nObjetivos espec\u00edficos:\n1.\tQuantificar n\u00edveis plasm\u00e1ticos de zinco, cobre e ferro em pacientes com leishmaniose cut\u00e2nea localizada, mucosa e visceral, comparando com controles urbanos e de \u00e1reas end\u00eamicas;\n2.\tQuantificar resposta imune celular m\u00fa-Leishmania in vitro (linfoprolifera\u00e7\u00e3o e produ\u00e7\u00e3o de citocinas) nos mesmos grupos;\n3.\tQuantificar resposta imune humoral (IgG m\u00fa-Leishmania plasm\u00e1tico) nos mesmos grupos.\n10\nJUSTIFICATIVA\nSegundo a OMS, as leishmanioses encontram-se entre as seis doen\u00e7as infecto-contagiosas de maior import\u00e2ncia no mundo desde o ultimo s\u00e9culo, sendo esta a causa de sofrimento de 350 milh\u00f5es de mulheres, homens e crian\u00e7as em 88 paises. Noventa porcento de todos os casos de LV ocorrem em Bangladesh, Brasil, \u00edndia e Sud\u00e3o e 90% dos casos de LC ocorrem no Afeganist\u00e3o, Brasil, Ir\u00e3, Peru, Ar\u00e1bia Saudita e Siria. Apesar das medidas adotadas nos programas de controle, nos \u00faltimos 10 anos, a doen\u00e7a vem se tornando end\u00e9mica em varias regi\u00f5es do mundo, aumentando sua incid\u00eancia. (OMS, on line, 2004).\nV\u00e1rias estrat\u00e9gias t\u00eam sido desenvolvidas com a finalidade de controlar a doen\u00e7a, desde entender a biologia dos vetores, identificar poss\u00edveis reservat\u00f3rios e elimina\u00e7\u00e3o quando infectados, identifica\u00e7\u00e3o de \u00e1rea end\u00eamica e/ ou novo foco, diagn\u00f3stico dos pacientes e ensaios com vacina\u00e7\u00e3o. Al\u00e9m disso, fatores s\u00f3cio-econ\u00f4micos e culturais s\u00e3o importantes para compreender a distribui\u00e7\u00e3o da doen\u00e7a nas diversas regi\u00f5es brasileiras, como no Nordeste, que apresenta baixas condi\u00e7\u00f5es s\u00f3cio-econ\u00f4micas associadas \u00e0 maior incid\u00eancia e preval\u00eancia da LC e LV (MS-FNS, 2000; MS, 2003).\nEstudos demonstraram o papel da nutri\u00e7\u00e3o na resposta imune (OLIVEIRA et al, 1990; BEISEL 1995; CHANDRA, 1997; PRASAD, 2000). A desnutri\u00e7\u00e3o pode ser causada pela falta de v\u00e1rios nutrientes e/ou micro-nutrientes, ou mesmo pela falta de apenas um nutriente ou micro-nutriente. O zinco (Zn) \u00e9 um micro-nutriente importante para o sistema imune e a sua defici\u00eancia leva a falha da resposta imune. Alguns estudos, demonstraram a import\u00e2ncia do papel do zinco na resposta imune in vitro e in vivo em doen\u00e7as infecciosas e n\u00e3o infecciosas\n11\n(PRASAD, 1983, 1995 e 2000; TURK, 1996; SAZAWAL et al., 1998). O Zn apresenta papel importante no metabolismo de macr\u00f3fagos, sendo um fator essencial na imunidade inata, e tem sido demonstrado seu papel crucial na imunidade mediada por c\u00e9lulas (PRASAD, 1995 &amp; CHANDRA, 1997). A relev\u00e2ncia do Zn na resist\u00eancia a infec\u00e7\u00f5es por virus, fungos e bact\u00e9rias \u00e9 reconhecido por sua efici\u00eancia em ativar o sistema imune, em particular em indiv\u00edduos soropositivos para HIV (MOCCHEGIANI &amp; MUZZIOLO, 2000). Evid\u00eancias experimentais com humanos e animais t\u00eam demonstrado que defici\u00eancia de zinco aumenta a susceptibilidade a doen\u00e7as infecciosas e n\u00e3o infecciosas e diminui a sobreviv\u00eancia em camundongos sendo, entretanto, corrigido com a sua suplementa\u00e7\u00e3o (PRASAD, 1991; MOCCHEGIANI et al., 1998). Em pessoas idosas saud\u00e1veis, foi observada diminui\u00e7\u00e3o da produ\u00e7\u00e3o de citocinas Thl como interferon-gama, o qual mostrou correla\u00e7\u00e3o com baixos niveis de zinco no soro, sendo a sua produ\u00e7\u00e3o restaurada por adi\u00e7\u00e3o de quantidades fisiol\u00f3gicas de zinco in vitro, enquanto que a produ\u00e7\u00e3o de IL-4 (citocina Th2) n\u00e3o foi afetada pela adi\u00e7\u00e3o de zinco (PRASAD, 2000).\nA Tabela 1 (anexo 1) e Tabela 2 (anexo 2) mostra o efeito da defici\u00eancia de zinco no sistema imune durante infec\u00e7\u00e3o e o aumento da susceptibilidade (MOCCHEGIANI &amp; MUZZIOLO, 2000; FRAKER et al., 2000). Na Tabela 2 (anexo 3), observa-se redu\u00e7\u00e3o significante da ocorr\u00eancia de infec\u00e7\u00e3o por suplementa\u00e7\u00e3o de zinco na hanseniase, mal\u00e1ria, diarr\u00e9ia, herpes cong\u00eanita, desnutri\u00e7\u00e3o e acrodermatite enterop\u00e1tica ((MOCCHEGIANI &amp; MUZZIOLO, 2000).\nNossos dados anteriores (anexo 4) demonstram que o zinco, em concentra\u00e7\u00f5es fisiol\u00f3gicas de 10 e 30|iM, exerce atividade leishmanicida em monocitos e macrofagos humanos infectados com L.amazonensis in vitro, sugerindo um possivel papel protetor do zinco na patog\u00eanese da leishmaniose humana.\n12\nSubject Heading: Clinical Immunology\nZINC/COPPER IMBALANCE AS A MARKER FOR IMMUNE\nDYSFUNCTION IN LEISHMANIASIS\nJohan Van Weyenbergh1, Gis\u00e9lia Santana1, Argemiro D\u2019Oliveira Jr3, An\u00edbal F Santos Jr4, Arlene Caldas3, Jackson M Costa3, Carlos H Costal Edgar M Carvalh^, Aldina Barral2, Manoel Barral-Netto1\nRunning title: Copper/zinc imbalance in leishmaniasis\nLIMI, ZLIP, Gon\u00e7alo Moniz Research Center-Oswaldo Cruz Foundation, 3Servi\u00e7o de Imunologia, HIJPES, 4Instituto de Qu\u00edmica, UFBA, Salvador-BA, 5N\u00facleo de Medicina Tropical, UFMA, S\u00e3o Luis-MA, and \u2018infectious Disease Hospital, UFPI, Teresina-PI, Brazil\nCorresponding author: Dr. Johan Van Weyenbergh, Funda\u00e7\u00e3o Oswaldo Cruz, CPqGM-\nLIMI, Rua Waldemar Falc\u00e3o 121, 40295-001 Salvador-BA, Brazil, Tel. +55 71 356 4320, Fax\n+55 71 356 2255, E-mail: johan\u00ae,cpqgm.f\u00edocruz.br\nABSTRACT\nMucosal (ML), localized cutaneous (LCL) and visceral leishmaniasis (VL) are characterized by exacerbated, intermediate and inefficient cellular immune response, respectively. We investigated if zinc and copper levels differ in distinct clinical forms of leishmaniasis, and if they correlate to humoral and/or cellular immune response towards the parasite. Blood was collected from 32 patients with either localized cutaneous (LCL), mucosal (ML) or visceral (VL) leishmaniasis, as well as from 25 controls from endemic and non-endemic areas. Anti-Leishmania humoral and cellular immune response were evaluated by quantifying specific plasma IgG, lymphoproliferation and cytokine production, respectively. A significant decrease in plasma Zn was observed in all three patient groups (p<0.01 for LCL and ML, p<0.001 for VL), as compared to controls, but only VL (7/10) and ML (1/7) patients displayed overt Zn deficiency. Plasma Cu was increased in LCL and VL (p<0.001) but not in ML, and was strongly correlated to zmi\\-l.eishmania IgG (Spearman r=0.65, p=0.0028). Cu/Zn ratios were highest in patients with deficient cellular (VL<<LCL<ML) and exacerbated humoral (VL>LCL>ML) immune response. In a prospective study of 12 VL patients, clinical and immunological data were obtained during a one-year follow-up. Zn deficient VL patients displayed a significant delay in spleen size normalization after treatment (p= 0.013).\nConclusions 1. Zn deficiency in VL and ML indicate possible therapeutic administration of Zn in these severe forms of leishmaniasis. 2. Plasma Cu positively correlates to humoral immune response across patient groups. 3. Increased Cu/Zn ratio can be a useful marker for immune dysfunction in leishmaniasis. 4. In VL patients, Zn levels may predict spleen size evolution.\nABBREVIATIONS\nML: mucosal leishmaniasis, LCL: localized cutaneous leishmaniasis, VL: visceral leishmaniasis.\nIntroduction\nLeishmaniasis is endemic in several parts of the world, with a global prevalence of over 12 million cases and 600,000 new cases emerging every year Q). The infection is caused by protozoan parasites of the genus Leishmania, transmitted trough the bite of the sand fly vector. Several Leishmania species are able to cause a wide spectrum of clinical manifestations, ranging from the mild cutaneous form, the disfiguring mucosal form and the life-threatening visceral form, also known as kala-azar. In Brazil, Leishmania (L.) hraziliensis causes cutaneous and mucosal disease, L. amazonensis causes cutaneous and, sporadically, visceral disease, while L. chagasi is exclusively associated with visceral disease. The clinical outcome of infection thus not only depends on the species involved, but also on the patient\u2019s immunocompetence. In recent years, a protective immune response against intracellular pathogens, such as Leishmania, Listeria and mycobacteria, has been defined as type 1 (Thl), whereas protection against extracellular pathogens, such as helminths, requires a type 2 (Th2) response. The murine model of experimental leishmaniasis has been instrumental for the elaboration of the Thl/Th2 paradigm, inasmuch as the preferential action of Thl (IFN-y, lL-12, TNF-a) or Th2 cytokines (IL-4, IL-5, IL-10) results in cure or progression of the disease, respectively (2, 3). In human leishmaniasis, this Thl/Th2 dichotomy is much less explicit for in vitro or ex vivo cytokine production. However, striking differences in cellular (lymphoproliferation and IFN-y production) and humoral (total and anti-Leishmania IgG) immune response can be observed in different clinical forms of the disease. Our group has recently shown that patients with localized cutaneous leishmaniasis (LCL) display a diminished Thl response during the eariy phase of disease, which is reverted after treatment (4). In mucosal leishmaniasis (ML), on the other hand, an exacerbated Thl response with increased IFN-y and TNF-a levels, is believed to provoke tissue destruction (5). In patients with visceral\nleishmaniasis (VL), characterized by immunosuppression and absence of and IFN-y production (6), we were able to show the beneficial effect IFN-y in vivo (7). Zinc deficiency has been shown to lead to a selective Th 1 deficiency in human volunteers (8). Surprisingly, only very few data are available on the role of Zn and Cu in human leishmaniasis (9), In this study, we investigated if Zn and Cu levels differ in different clinical forms of the disease, and if these trace metals might be correlated to ex vivo immune response towards the parasite.\nMethods\nBlood samples (10 ml heparinized tubes, Vacutainer) from 22 patients and 15 healthy controls (mostly patient\u2019s relatives) were obtained in an outpatient clinic in the district of Corte de Pedra, (Bahia state, Northeast of Brazil). This rural area has a low socio-economic status and a high incidence of infection with Leishmania hraziliensis and, sporadically, Leishmania amazonensis. During a one year period, 15 patients with LCL (single lesion with less than 4 weeks of duration) were selected and treated (20 mg/kg of Sbv (Glucantime) i.v. during 20 days). Of those, only 7 patients returned to draw blood after 3 months of treatment, but all patients cured during followup . Seven patients with ML were selected after several rounds of unsuccessful treatment and severe disease progression. Blood samples from 10 patients with VL were obtained from two different urban areas (Salvador-Bahia and Teresina-Piaui). Ten healthy urban controls were recruited among students and laboratory staff (Salvador-Bahia). Serial blood samples of 12 children with VL (S\u00e3o Luis-Maranh\u00f5) were obtained in a prospective study (one-year clinical and immunological follow-up).\nDiagnosis was confirmed by Montenegro skin test, serology, direct culture of parasites from lesions (4) or bone marrow aspiration for VL (7). This study was approved by the Ethics Committee of the University Hospital Edgard Santos, Salvador.\nCu and Zn were quantified by atomic absorption spectrophotometry (Varian 220) using an air/acetylene flame. One ml of plasma was diluted tenfold with 0.05 % Triton X-100, 1 % HNO3, sonicated for 10 min and analysed in triplicate. All reagents used were analytical grade (Merck). Due precautions were taken to avoid external and internal (hemolysis) trace metal contamination.\nIn order to investigate the influence of trace metals, antibodies and other endogenous plasma components, such as cytokines, on the ex vivo cellular immune response, we used a recently described model using whole blood and live Leishmania promastigotes (10), closely mimicking the early in vivo events following a sandfly bite. Whole blood was diluted tenfold in culture medium (RPMl supplemented with L-glutamine and gentamycin, all from Gibco-BRL) and stimulated with L. amazonensis promastigotes (105/mL). Supernatants were collected after 72 h of culture and frozen in aliquots for cytokine determination. Lymphoproliferation was quantified by measuring [3H]-thymidine incorporation after 120 h of culture. IFN-y in culture supernatants was quantified using a commercial ELISA kit (DuoSet, Genzyme).\nResults\nA significant decrease in plasma Zn was observed for both LCL and ML patients, as compared to controls from the same endemic area (0.80 \u00b1 0.04 and 0.77 \u00b1 0.05 vs. 1.01 \u00b1 0.06 pg/m.L, p<0.01, Figure lA), and in VL patients, as compared to urban controls (0.55 \u00b1 0.08 vs. 0.83+/-0.03 pg/mL, p<0.001, Figure lA). Zn deficiency (plasma Zn&lt;0.65 (ig/mL), however, was observed only in VL (7/10) and ML (1/7) patients. As shown in Fig. IB, plasma Cu was significantly increased in LCL (1.32 \u00b1 0.10 vs. 1.01 \u00b1 0.05 pg/mL, p<0.001) and VL (1.42 \u00b1 0.13 vs. 0.72 \u00b1 0.06 ng/mL, p<0.001), but not in ML (1.04 \u00b1 0.05 vs. 1.01. \u00b1 0.05). After three months of treatment, plasma Zn increased and Cu decreased in LCL patients, resulting in values indistinguishable from endemic controls. Although within normal physiological ranges (11). Cu and Zn levels were significantly increased in healthy controls from the endemic area, as compared to urban controls (p<0.01. Fig, lA and IB) . Cu/Zn ratios, however, were similar in both control groups (p=0 .115), but significantly increased in all three patient groups (Fig . 1C), reaching a three-fold molar excess of Cu to Zn in VL patients.\nTo determine if these observations reflect possible changes in the patients' immune status, we quantified humoral and cellular anti-l.eishma.nia immune response ex vivo and correlated them to trace element levels. When comparing patient groups, a stepwise increase in m\\ti-Leishmania IgG and Cu/Zn ratio can be observed, with ML<LCL<VL (Table I and Fig.l). In addition, a highly significant correlation between plasma Cu, but not Zn or Cu/Zn ratio, and anti-l.eishmania IgG was observed across patient groups (Fig. 2, Spearman r=0.65, p=0.0028). Since lymphoproliferation and IFN-y production were virtually absent in VL, correlation with trace element levels across patient groups could not be calculated, but an inverse order was observed,\nwith ML>LCL\u00bbVL (Table I) as compared to Cu/Zn ratio with ML<LCL<<VL (Fig. 1), confirming reciprocal regulation of Thl/cellular immune response and Th2/humoral immune response:.\nSince Zn deficiency was striking in VL patients, we evaluated its clinical and immunological impact in a prospective study comprising 12 children with VL. Fifty percent (6/12) were Zn deficient before treatment (Table II), one quarter (3/12) remained Zn deficient after treatment (30 days), but all of them returned to normal values at three months of treatment (data not shown). All patients restored clinical and immune parameters during a one-year follow-up. No significant differences were observed in cellular (DTH conversion and in vitro IFN-y production) and humoral {mti-Leishmania IgG) immune response between Zn deficient and Zn sufficient patients (Table II). However, Zn deficient patients displayed a significantly lower decrease in spleen size after treatment (30 days), as compared to Zn sufficient patients (Table II, p = 0.013), three of which had already complete regression of spleen size.\nDiscussion\nAlthough plasma Zn was significantly decreased in all three patient groups, plain Zn deficiency was only observed in seven VL patients and one ML patient, being absent in LCL patient and in both control groups. In parallel, plasma Cu in VL patients increased to levels which have been shown to be toxic in vitro (12). In addition, a highly significant positive correlation between plasma Cu and parasite-specific IgG across patient groups suggests that the trace element might interfere in anti-Leishmania immune response, e.g. by leading to a non-protective Th2/humoral immune response, known to be exacerbated in visceral leishmaniasis. Increased plasma Cu cannot be considered as a mere marker of inflammation, since it was not observed in\nML, a chronic inflammatory condition characterized by high production of pro-inflammatory cytokines, such as TNF-a. and IFN-y (5). Since our in vitro findings indicate Zn as a macrophage activator (Van Weyenbergh et al., unpublished results), the significant decrease in Zn in ML patients might be responsible for the inability of the patients to clear the parasite, in spite of high IFN-y levels and several rounds of treatment. A direct correlation between Zn levels and parasite burden was also suggested by the significant delay in spleen size normalization in Zn deficient VL patients (Table II).\nLCL patients represent an intermediate group between ML and VL, displaying a detectable, but variable humoral and cellular immune response with production of both Thl and Th2 cytokines, undergoing a shift towards the Thl/cellular pole after successful treatment (4). We observed a reciprocal association between Cu/Zn levels and humoral and cellular immune response in untreated LCL patients, and a complete reversal of increased Cu/Zn ratios after treatment. Taken together, these data indicate that Cu/Zn imbalance might serve as a marker for decreased Thl response and immunodeficiency in leishmaniasis, being more pronounced in its most severe and possibly fatal visceral form. Concordant with this hypothesis, VL patients from Teresina display increased Cu/Zn ratios (Fig. 1), as compared to VL patients from S\u00e3o Luis (Table II), all of which effectively cured with standard antimonial therapy. Unfortunately, no clinical follow-up was possible in Teresina, but mortality, mostly due to coinfections, and therapeutic failure occur in 6,1 % of the cases (13, 14), whereas mortality and therapeutic failure has been absent in a large cohort of VL patients in S\u00e3o Luis followed for the last four years (Caldas A. &amp; Costa J., unpublished results).\nIt is tempting to speculate that environmental exposure to copper might increase susceptibility to Leishmania and other intracellular pathogens, such as Listeria and mycobacteria, e.g. by directly interfering with cytokine production as previously shown (15). Increased plasma Cu in\nendemic controls might reflect the use of Cu as a fungicide in cocoa plantations in the Corte de Pedra area . It should be stated that spouses and relatives were preferentially chosen as endemic controls, since environmental exposure and nutritional status are far more important determinants for Cu and Zn levels than sex or age (H). Long-term follow-up of treated patients and comparison with other endemic areas might learn if trace metal levels have predictive value for clinical evolution of and/or susceptibility to leishmaniasis. In addition, we propose that trace metal levels should be taken into account in vaccine strategies for leishmaniasis, because of the importance of Zn in a protective Thl response (8) and because of the possibly deleterious effect of Cu described in this study. Two recent large-scale vaccination trials for cutaneous and visceral leishmaniasis (16, 17) were carried out in regions where Zn deficiency is prevalent, namely Iran and Sudan, which might have contributed in part to the low protection rate observed in both trials.\nAdministration of Zn in vivo has been shown to down-regulate increased Cu levels in patients with Wilson disease and to revert its toxicity (18), suggesting that systemic administration of Zn might be beneficial in addition to its direct immunostimulatory effect (8). A recent report (19) demonstrated the safety and efficiency of oral Zn in Old World cutaneous leishmaniasis, a mild and self-healing form of the disease, with patients displaying normal Zn levels. Our results strongly suggest that zinc therapy should be considered in the mucosal and visceral forms of leishmaniasis, associated with high morbidity and mortality, as well as frequent failure of antimonial therapy.\nIn conclusion, our data indicate that Cu/Zn imbalance can be a useful marker for immune dysfunction in leishmaniasis and suggest that trace metals are implicated in miX-Leishmanla immune response, which should direct future therapeutic intervention.\nACKNOWLEDGMENTS\nWe thank the patients, their families, the field workers and the medical staff' from the Corte de Pedra outpatient clinic and from UFMA and UFPI University Hospitals; Andr\u00e9 B\u00e1fica, George Soares, Jorge Tolentino and Silvia Cardoso for practical assistance; Dr Maria das Gra\u00e7as Korner for advice on trace element analysis and Dr Cla\u00fadia Brodskyn for critical reading of the manuscript . Financial support; NIH (TMRC grant AI-30639), PIBIC-UFBA, CAPES, CNPq (Brazilian National Research Council) and PRONEX. EMC, AB and MBN are CNPq investigators.\nREFERENCES\n1.\tDesjeux P. Human leishmaniasis: epidemiology and public health aspects. World Health Stat Q 1992, 45:267-75.\n2.\tCoffman RL, Chatelain R, Leal LM, Varkila K. Leishmania major infection in mice: a model system for the study of CD4+ T-cell subset differentiation. Res Immunol 1991;142:36-40.\n3.\tReiner SL, Locksley RM' . The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-77.\n4.\tRocha PN, Almeida RP, Bacellar O, de Jesus AR, Filho DC, Filho AC. et al. Down-regulation of Thl type of response in early human American cutaneous leishmaniasis. J Infect Dis 1999;180:1731-4.\n5 . Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res 1998;31:143-8.\n6.\tCarvalho EM, Badaro R, Reed SG, Jones TC, Johson WD Jr. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 1985;76:2066-\n9.\n7.\tBadaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A. et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990; 322:16-21.\n8 . Beck FW, Prasad AS, Kaplan J, Fitzgerald JT, Brewer GJ. Changes in cytokine production and T cell subpopulations in experimentally induced zinc-deficient humans. Am J Physiol 1997;272:E 1002-7.\n9.\tKocyigit A, Erel O, Gurel MS, Avci S, Akteje N. Alterations of serum selenium, zinc, copper, and iron concentrations and some related antioxidant enzyme activities in patients with cutaneous leishmaniasis. Biol Trace Elem Res 1998;65:271-81.\n10.\tDominguez M, Torano A. Immune adherence-mediated opsonophagocytosis: the mechanism of Leishmania infection. J Exp Med 1999;189:25-35.\n11.\tBogden JD, Kemp FW, Han S, Li W, Bruening K, Denny T, et al. Status of selected nutrients and progression of human immunodeficiency virus type 1 infection. Am J Clin Nutr 2000;72:809-15.\n12 . Aston NS, Watt N, Morton IE, Tanner MS, Evans GS. Copper toxicity affects proliferation and viability of human hepatoma cells (HepG2 line). Hum Exp Toxicol 2000;19:367-76\n13. Santos MA, Marques RC, Farias CA, Vasconcelos DM, Stewart JM, Costa DL, Costa CH. Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis. Rev Soc Bras Med Trop 2002;35:629-33.\n14 . Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Wemeck GL, Batista MS, Gomes JR, Costa DL, Costa CH. Infection 2003;31:174-7.\n15. Theocharis S, Margeli A, Panayiotidis P. Effects of various metals on DNA synthesis and lymphokines production by human peripheral blood lymphocytes in vitro. Comp Biochem Physiol C 1991;99:131-3.\n16\t. Sharifi 1, FeKri AR, Aflatonian MR, Aflatonian MR, Khamesipour A, Nadim A. et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998:351: 1540-3.\n17\t. Khalil EA, El Hassan AM', Zijlstra EE, Mukhtar MM, Ghalib H W, Musa B. et al. Autoclaved\nLeishmania major vaccine for prevention of visceral leishmaniasis: a randomised, doubleblind, BCG-controlled trial in Sudan. Lancet 2000;356:1565-9.\n18\t. Brewer GJ Recognition, diagnosis, and management of Wilson's disease. Proc Soc Exp Biol\nMed 2000;223:39-46.\n19\t. Sharquie KE, Najim RA, Farjou IB, Al-Timimi DJ. Oral zinc sulphate in the treatment of\nacute cutaneous leishmaniasis. Clin Exp Dermatol 2001;26:21-6.\nTABLE I : Characteristics and immune parameters of patient groups and controls\nGroup (n)\tAge\tMale/ Female\tAnti- Leishmania IgG (arbitrary units)\tLymphoproliferation (cpm)\"\tIFN-y (pg/mL)b\nUrban controls (10)\t24.9(2.0)\t7/3\t&lt;cut-off\t&lt;100\t<20\nEndemic controls (15)\t28.7(8.8)\t3/12\t&lt;cut-offa\tND\t<20\nLCLO (15)\t28.4(12.7)\t11/4\t177.5 (73.0)\t2737 (1178)\t612(207)\nLCL3 (7)\t28.5 (11.2)\t5/2\t73.5 (20.9)\tND\t685 (348)\nML (7)\t44.4 (11.9)\t5/2\t15.8(4.6)\t> 5000\t>2000\nVL (10)\t18.4 (3.8)\t6/4\t187.8 (72.1)\t&lt;100\t<20\nResults are expressed as mean (SEM). ND: not done. LCLO and LCL3, localized cutaneous leishmaniasis at 0 and 3 months of treatment, ML mucosal leishmaniasis, VL visceral\nTABLE II : Characteristics and immune parameters of prospectively studied VL patients\n\tZn deficient (n = 6)\tZn sufficient (n = 6)\tStatistical analysis\nAge (years)\t2.8 \u00b10.9\t4.4 \u00b1 1.1\tp = 0.30\nSex\t2F/4M\t4F/2M\tp = 0.57\nPlasma Zn (p.g/ml)\t0.46 \u00b10.02\t1.05\u00b1tO.O5\tp &lt;0.0001\nPlasma Cu (jig/ml)\t0.64 \u00b10.15\t0.85 \u00b10.11\tp = 0.30\nCu/Zn ratio\t1.45 \u00b10.26\t0.83 \u00b10.13\tp = 0.11\nDisease duration (weeks)\t5.0 \u00b1 1.0\t10.3 \u00b15.2\tp = 0.34\nSpleen before treatment (cm)\t6.8 \u00b10.5\t5.3 \u00b1 1.2\tp = 0.28\nSpleen after treatment (cm)\t3,7 \u00b10.3\t1.5\u00b10.7\tp = 0.013\nLiver before treatment (cm)\t7.3 \u00b10.6\t7.3 \u00b1 0.4\tp= 1.00\nLiver after treatment (cm)\t5.2 \u00b10.7\t5.0 \u00b10.5\tp = 0,85\nDTH conversion (months)\t8.8\u00b1 1.3\t8.5 \u00b1 1.6\tp = 0.87\nIgG anti-Leishmania (OD)\t0.51 \u00b10.16\t0.57 \u00b10.18\tp = 0.80\nIFN-y (pg/ml)\t<20\t25 \u00b121\tp = 0.29\nFIGURE LEGENDS\nFigure 1: Plasma levels of Zn and Cu in controls and patients\nBars represent mean (+/- SEM) Zn (A) and Cu (B) plasma levels, and plasma Cu/Zn ratios (C) of urban (U) and endemic (E) controls; and patients with mucosal leishmaniasis (ML), localized cutaneous leishmaniasis before (LCLO) and after 3 months of treatment (LCL3), and visceral leishmaniasis (VL). *p<0.05, **p<0.01, ***p&lt;.001 for LCLO and ML vs. E and for VL vs, U (Mann-Whitney test).\nFigure 2 Correlation between plasma Cu and anti-Leishmania. IgG\nPlasma levels of Cu and aiti-Leishmania IgG were positively correlated in patients with localized cutaneous leishmaniasis before treatment (LCL), mucosal leishmaniasis (ML) and visceral leishmaniasis (VL) (Spearman r=0.65, p=0.0028).\nrank anti-Leishmania IgG\nDISCUSS\u00c3O E PERSPECTIVAS\nDoen\u00e7as parasitarias e desnutri\u00e7\u00e3o permanecem como os maiores problemas de sa\u00fade nas \u00e1reas tropicais e subtropicais. A aten\u00e7\u00e3o tem sido recentemente focalizada na desnutri\u00e7\u00e3o como fator de risco para o desenvolvimento de tais doen\u00e7as e vice versa. Estudos cl\u00ednicos t\u00eam sido limitados pela multiplicidade de fatores que contribuem para a desnutri\u00e7\u00e3o, como: varia\u00e7\u00f5es nas defici\u00eancias que resultam em um quadro de desnutri\u00e7\u00e3o, alta freq\u00fc\u00eancia de parasitas e infec\u00e7\u00f5es bacterianas ent\u00e9ricas entre pessoas que vivem em \u00e1reas com condi\u00e7\u00f5es higi\u00eanicas prec\u00e1rias. Contudo, de acordo com a OMS, crian\u00e7as gravemente desnutridas t\u00eam infec\u00e7\u00f5es bacterianas na ocasi\u00e3o da admiss\u00e3o para tratamento hospitalar, principalmente infec\u00e7\u00f5es do trato respirat\u00f3rio inferior. Diferentemente das crian\u00e7as bem nutridas, que respondem a infec\u00e7\u00f5es como febre e inflama\u00e7\u00e3o, crian\u00e7as desnutridas com infec\u00e7\u00f5es s\u00e9rias podem se tomar apenas ap\u00e1ticas ou sonolentas, sendo, portanto, importante o tratamento precoce de infec\u00e7\u00f5es bacterianas com antimicrobiano efetivo, a fim de melhorar a resposta nutricional \u00e1 alimenta\u00e7\u00e3o.\nAlguns autores prop\u00f5em, a partir de estudos sobre LV em \u00e1reas end\u00eamicas no Brasil e de infec\u00e7\u00e3o experimental com hamster s\u00edrio, que a doen\u00e7a constitui um excelente modelo para avaliar a inter-rela\u00e7\u00e3o entre desnutri\u00e7\u00e3o e infec\u00e7\u00e3o parasit\u00e1ria. A desnutri\u00e7\u00e3o parece influenciar no curso da doen\u00e7a, mas n\u00e3o na susceptibilidade da infec\u00e7\u00e3o. Por\u00e9m, outros estudos t\u00eam demonstrado que a infec\u00e7\u00e3o por L.chagasi ocorre em crian\u00e7as de \u00e1reas end\u00eamicas independentemente do estado nutricional (CALDAS et al, 2001).\nApesar de existirem estudos dedicados \u00e1 import\u00e2ncia do zinco na resposta imune in vitro e in vivo em algumas doen\u00e7as infecciosas e n\u00e3o-infecciosas (PRASAD, 1995). poucos s\u00e3o os\n13\ndados sobre o poss\u00edvel papel do zinco na patog\u00eanese da leishmaniose humana. Apenas um estudo mostra baixos n\u00edveis s\u00e9ricos de zinco e de ferro em pacientes turcos com LC, ambos corrigidos ap\u00f3s tratamento com antimonial pentavalente (Sb+5) (KOCYIGIT et al., 1998). Esta diminui\u00e7\u00e3o, ou at\u00e9 marcante defici\u00eancia de zinco, como observamos em nossos pacientes, \u00e9 um assunto de significativo interesse para o entendimento do processo patol\u00f3gico, considerando que o zinco \u00e9 essencial para o funcionamento da imunidade celular (CHANDRA, 1997). Tanto em pacientes como em modelos animais de leishmaniose, a imunidade celular \u00e9 capaz de conferir prote\u00e7\u00e3o, enquanto que a ativa\u00e7\u00e3o da imunidade humoral correlaciona com susceptibilidade e progress\u00e3o da doen\u00e7a. Nossos dados, n\u00e3o permitem estabelecer uma causalidade entre dist\u00farbios e/ou defici\u00eancias no metabolismo do zinco e evolu\u00e7\u00e3o da doen\u00e7a, mas, indicam este metal como alvo terap\u00eautico. Por outro lado, apesar de estar significativamente diminu\u00eddos nos pacientes com LV, os n\u00edveis plasm\u00e1ticos de ferro n\u00e3o se correlacionaram com a resposta imune m\u00fa-Leishmania em nenhum dos grupos estudados (dados n\u00e3o mostrados).\nO zinco \u00e9 freq\u00fcentemente ntilizado como terapia pa doen\u00e7a n\u00e7 WH son, dnen\u00e7a autoss\u00f4mica recessiva na qual ocorre desordem levando o ac\u00famulo de cobre (Cu) primariamente dentro do f\u00edgado e sub^q\u00fcentemente no sistema neurol\u00f3gico e em outros tecidos, caso o tratamento especifico n\u00e3o seja feito, o ac\u00famulo de cobre \u00e9 progressivo e fatal (SCHILSKY et al, 2001). O zinco atua tanto na competi\u00e7\u00e3o com o Cu por absor\u00e7\u00e3o no sitio luminal do epit\u00e9lio intestinal, quanto na indu\u00e7\u00e3o da s\u00edntese da metalotioneina, reduzindo dessa maneira os n\u00edveis de Cu e prevenindo sua reacumula\u00e7\u00e3o em tecidos (BREWER et al., 1998). Nossos dados mostram um aumento nos n\u00edveis plasm\u00e1ticos de cobre, aparente tanto nos pacientes com LCL e LV, como nos controles da \u00e1rea end\u00eamica, sugerindo que, al\u00e9m da patologia, fatores ex\u00f3genos (exposi\u00e7\u00e3o ambiental, nutri\u00e7\u00e3o,...) podem interferir com o metabolismo do cobre e do zinco.\n14\nSharquie et al. (2001), em ensaio cl\u00ednico randomizado incluindo 102 pacientes Iraquianos acometidos pela LCL causada por L.major e L.tropica e tratados com sulfato de zinco por via oral, observaram cura acelerada da doen\u00e7a, mesmo na aus\u00eancia de defici\u00eancia de zinco. As rea\u00e7\u00f5es adversas foram brandas, demonstrando o zinco como uma boa op\u00e7\u00e3o terap\u00eautica das manifesta\u00e7\u00f5es cut\u00e2neas da leishmaniose no Velho Mundo.\nEm conclus\u00e3o, o nosso estudo poderia indicar futuros ensaios cl\u00ednicos utilizando o zinco, na forma t\u00f3pica ou oral, na LT e LV no Brasil. Vale ressaltar as vantagens do uso terap\u00eautico do zinco, j\u00e1 comprovado no tratamento de diversas doen\u00e7as, que s\u00e3o o baixo custo e a quase aus\u00eancia de toxicidade ou efeitos colaterais, em contraste ao tratamento atual com antimoniais pentavalentes (antimoniato-N-metilglucamina e estibogluconato de s\u00f3dio).\n15\nCONCLUS\u00d5ES\n1.\tA defici\u00eancia de Zn na LV e LM indica a possibilidade da administra\u00e7\u00e3o terap\u00eautica de Zn nessas formas severas da leishmaniose;\n2.\tOs n\u00edveis plasm\u00e1ticos de Cu correlacionaram-se positivamente com resposta imune humoral entre os pacientes com LV, LCL e LM;\n3.\tA raz\u00e3o Cu/Zn pode funcionar como marcador de disfun\u00e7\u00e3o imune nas leishmanioses humana;\n4.\tA defici\u00eancia de zinco pode ser preditivo de retardo na diminui\u00e7\u00e3o de tamanho do ba\u00e7o em pacientes com LV.\n16\nREFERENCIAS BIBLIOGR\u00c1FICAS\nBADAR\u00d3, R, Editorial. Progressos nas pesquisas de Leishmaniose visceral na \u00e1rea end\u00e9mica de Jacobina-Bahia 1934-1989. Rev. Soc. Bras. Med. Trop., 21:159-164, 1998.\nBADAR\u00d3, R.; JONES, T.C.; LOREN\u00c7O, R.; CERF, B.J. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J. Infect. Dis., 154:1003-1011, 1986.\nBARRAL, A.; PEDRAL, S. D.; GRIMALDI JUNIOR, G.; MOMEN, H.; MCMAHON, P.D., RIBEIRO, A.J.; ALMEIDA, R,; BADARO, R.; BARRAL-NETTO, M.; CARVALHO, E.M. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am. J. Trop. Med.Hyg, 44:536, 1991.\nBEISEL, R.W.; HERMAN, A. L. Infection-induced malnutrition- from cholera to cytokines. Am. J. Clin. 62:813-819, 1995.\nBITTENCOURT, A.L.; BARRAL-NETTO, M. Leishmaniasis. In: DOERR, W.; SEIFERT, G. (Eds.). Tropical Pathogy. Berlin: Springer-Verlag, 1995. p.597-651.\nBRASIL. Minist\u00e9rio da Sa\u00fade. Centro Nacional de Epidemiolog\u00eda. Funda\u00e7\u00e3o Nacional de Sa\u00fade, Leishmaniose Tegumentar Americana no Brasil. 5-54, 1998.\nBRASIL. Minist\u00e9rio da Sa\u00fade. Centro Nacional de Epidemiolog\u00eda. Funda\u00e7\u00e3o Nacional de Sa\u00fade, Manual de Controle de Leishmaniose Tegumentar Americana. 7-59, 2000.\nBRASIL. Minist\u00e9rio da Sa\u00fade . Manual de vigil\u00e2ncia e Controle da Leishmaniose Visceral. 9:83, 2003.\n17\nBREWER, G.J.; DICK, R.D.; JOHNSON, V.D.; BRUNBERG, J.A.; KLUIN, K.J.; FINK, J.K. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J. Lab. Clin. Med., 132:264-268, 1998.\nCALDAS, A.J.M.; AQUINO, D.M.C.; BARRAL, A.P.; COSTA, J.M.L. Avalia\u00e7\u00e3o nutricional das crian\u00e7as de zero a cinco anos de idade de \u00e1rea end\u00eamica de leishmaniose visceral americana (LVA). Rev. Hosp. Univ. Maranh\u00e3o, 2:9-14, 2001.\nCAMPOS JUNIOR, D. Caracter\u00edsticas cl\u00ednico-epidemiol\u00f3gicas do calazar na crian\u00e7a. J. Pediatr., 71:26^1-265, 1995.\nCHANDRA, R.K. Nutrition and the immune system: an introduction. Am. J. Clin. Nutr., 66: 460S, 1997. Suplemento.\nDE OLIVEIRA, J.E.; FAVARO, R.M.; DESAI, I . D. Progress in the diagnosis of hypovitaminosis A: clinical and biochemical correlations. Arch. Latinoam. Nutr., 40:333-348, 1990.\nDILLINGHAM, R.; GUERRANT R.L.; Childhood stunting: measuring and stemming the staggering costs of inadequate water and sanitation. Lancet, 363:94-95, 2004.\nDYE, C.; WILLIAMS B.G. Malnutrition, age and the risk of parasitic disease: visceral leishmaniasis revisited. Froc. R. Soc. London, 254, 33-39, 1993.\nFRAKER, P.J.; KING, L.E.; LAAKKO, T.; VOLLMER, T.L. The dynamic link between the integrity of the immune system and zinc status. J. Nutr., 130:1399S, 2000.\nHARRISON, L.H.; NAIDU, T.G., DREW, J.S.; ALENCAR, J.E.; PEARSON, R.D. Reciprocal relationships between undemutrition and the parasitic disease visceral leishmaniasis. Rev. Infect. Dis., 8:447-452, 1986.\n18\nHEINZEL, F.P.; SADICK, M.D.; HOLADAY, B.J.; COFFMAN, R.L.; LOCKSLEY, R.M. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med., 169: 59, 1989.\nKOCYIGIT, A.; EREL, O.; GUREL, M.S.; AVCI, S.; AKTEJE, N. Alterations in serum selenium, zinc, copper and iron concentrations and some related antioxidant enzyme activities in patients with cutaneous leishmaniasis. Biol. Trace Elem. Res., 65:271-281, 1998.\nLAINSON, R.; SHAW J.J. Evolution, classification and geographical distribution. In; PETER, W.; KILLICH, R.K. The Leishmaniasis in the New World. Biology And Medicine. London; Academic Press, 1987.\nLAINSON, R; SHAW J.J.; READY, P.D.; MILES, M.A.; POVOA, M. Leishmaniasis in Brazil; XVI. Isolation and identification of Leishmania species from sandflies, wild mammals and man in north Para State, with particular reference to L. braziliensis guyanensis causative agent of \"pian-bois\". Trans. R. Soc. Trop. Med. Hyg., 75:530-536, 1981.\nLOCKSLEY, R.M.; PINGEL, S.; LACY, D.; WAKIL, A.E.; BIX, M.; FOWELL, D.J. Susceptibility to infectious diseases: Leishmania as a paradigm. J. Infect. Dis., 179; Suppl 2, S305, 1999.\nLUZ, G.K.; SUCCI, M.C.R.; TORRES, E. Nivel s\u00e9rico da vitamina A em crian\u00e7as portadoras de leishmaniose visceral. Rev. Soc. Bras. Med. Trop., 34;381-384, 2001.\nMOCCHEGIANI, E.; MUZZIOLI, M. Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections. J. Nutr., 130;1424S, 2000.\nMOCCHEGIANI, E.; SANTARELLI, L.; TIBALDI, A.; MUZZIOLI, M.; BULIAN, D.; CIPRIANO, K.; OLIVIERI, F.; FABRIS, N. Presence of links between zinc and melatonin during\n19\nthe circadian cycle in old mice: effects on thymic endocrine activity and on the survival. J. Neuroimmunol, 86:111, 1998.\nPASSOS, V.M.; FALCAO A.L.; MARZOCHI M.C.; GONTIJO C.M.; DIAS E.S.; BARBOSA,\nE.G.S.; GUERRA H.L.; KATZ, N. Epidemiological aspects of American cutaneous leishmaniasis in a periurban area of the metropolitan region of Belo Horizonte, Minas Gerais, Brazil. Mem. Inst. Oswaldo Cruz,l: 103-110, 1993.\nPEARSON, R.D.; WHEELER, D.A.; HARRISON, L.H.; KAY, H.D.; The immunobiology of leishmaniasis. Rev. Infect. Dis., 5:907-927, 1983.\nPRASAD, A . S. Discovery of human zinc deficiency and studies in an experimental human model. Am. J. Clin. Nutr., 53:403, 1991\nPRASAD, A .S. Effects of zinc deficiency on Thl and Th2 cytokine shifts. J. Infect. Dis., 182: Suppl 1, S62, 2000.\nPRASAD, AS. Zinc: an overview. Nutrition, 11:93, 1995.\nPRASAD, A . S. Clinical, Biochemical and Nutritional Spectrum of Zinc deficiency in Human Subjects: An Update. Nutr. Rev., 41:197-208, 1983\nPRASAD, A .S. Zinc deficiency. B.M.J., 326:409-10, 2003.\nQUEIROZ, R.G.; de VASCONCELOS, LA.; VASCONCELOS, A.W.; PESSOA, F.A.; de SOUSA, R.N.; DAVID, J.R. Cutaneous leishmaniasis in Ceara state in northeastern Brazil: incrimination of Lutzomyia whitmani (Diptera: Psychodidae) as a vector of Leishmania braziliensis in Baturite municipality. Am. J. Trop. Med. Hyg., 50:693-698, 1994.\nRINK, L.; KIRCHNER, H. Zinc-Altered Immune Function and Cytokine Production. J. Nutr., 130:1407S-1411S, 2000.\n20\nSAZAWAL, S.; BALCK R.E.; JALLA, S.; MAZUMDAR, S.; SINHA, A.; BHAN M.K. Zinc Supplementation Reduces the Incidence of Acute Lower Respiratory Infections in Infants and Preschool Children: A Double-blind, Controlled Trial. Pediatrics, 102:1-5, 1998.\nSCHILSKY, M . L. Diagnosis and treatment of Wilson's disease. Pediatr. Transpl., 6:15, 2002.\nSCOTT, P.; NATOVITZ, P.; COFFMAN, R.L.; PEARCE, E.; SHER, A. Immunoregulation of cutaneous leishmaniasis T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med., 168:1675-1684, 1989.\nSHARQUIE, K.E.; NAJIN, R.A.; FARJOU, I.E.; AL-TIMIMI, D.J. Oral zinc sulphate in the treatment of cutaneous leishmaniasis. Clin. Exp. Dermatol., 26:21-26, 2001.\nSILVA, A.R.; VIANA, G.M.C.; VARONIL, C.; PIRES, B.; NASCIMENTO, M.D.S.B.; COSTA, J.M.L. Leishmaniose Visceral (calazar) na Ilha de S\u00e3o Lu\u00eds, Maranh\u00e3o, Erasil. Evolu\u00e7\u00e3o e perspectivas. Rev. Soc. Bras. Med. Trop., 30:359-368, 1997.\nSILVA, J.R. Leishmaniose visceral (Calazar). 1957. Tese (Doutorado) - Servi\u00e7o de Educa\u00e7\u00e3o Sanit\u00e1ria. Rio de Janeiro.\nSILVEIRA, F.T.; LAINSON, R.; SHAW J.J.; de SOUZA, A.A.; ISHIKAWA, E.A.; ERAGA, R.R. Cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis in Amazonian Brazil, and the significance of a negative Montenegro skin-test in human infections. Trans. R. Soc. Trop. Med. Hyg., 85:735-738, 1991.\nTURK, S.; BOZFAKIOGLU, S.; ECDER, S .T.; KAHRAMAN, T.; GUREL, N.; ERKO\u00c7, R.; AYSUNA, N.; TURKMEN, A.; BEKIROGLU, N.; ARK, E. Effects of zinc supplementation on the immune system and on antibody response to multivalent influenza vaccine in hemodialysis patients, int. J. Artif. Organs, 21:274-278, 1998.\n21\nVEXENAT, J.A.; BARRETTO, AC.; CUBA, C.A.C.; MARSDEN, P.D. Epidemiological Characteristics of American cutaneous leishmaniasis in an endemic region of the State of Bahia.\nIII.\tPhlebotomine fauna. Mem. Inst. Oswaldo Cruz, 81:293-301, 1986a.\nVICTORA,G. C.; VAUGHAN P.J.; KIRKWOOD, R.B.; MARTINES, C.J.; BARCELOS, B.L. Risk Factors for Malnutrition in Brazilian Children: the role of social and environmental variables. Bull. WHO, 64:299-309, 1986.\nWORLD HEALTH ORGANIZATION - WHO. Control of the leishmaniasis. WHO. Tech. Rep. Ser., 793:1-158, 1990.\n22\nTABLE 1\nEffect of zmc deficiency an knimme system during m faction and susceptibility to various pa\u00c9togens during infectious episodes\nImmuns system @fjsdi\tPethogensy\nThymic atrophy in HIV Decreased thymocytes count Decreased thymulin ievels Decreased peripheral T-cell count Decreased delayed hyperscnsitivity Decrsasad proliferative response to PHA Decreased T-colI cytotoxic activity Decreased T-heiper function Decrsased natural killer activity Dsc^^ed imecraphye function Decreased neutrophil function Decreased antibody formation Decreased IL-2, IL-12, IFN-\u00ab Increased IL-1, IL-6, T'FN-y Increassd thymic apoptosis Reduced DM-.-Repairs Altered eatrathymic T-oell pethw\u00ae\tHerpes simplex virus Semliki forest virus Fram.fseMa Mamntis Listeria monocytogas&amp;s SakmmM mtofitHs Gram-negative bacteria Mycc&amp;acttm'um tubmcok&amp;fs Tryjxmossma cwzf Trypmnosoma mmxiuli Trffpmosama gondii Rosmodium yoeiii Candida aUbioam Rasmodium ptebapmum He^pooomn&amp;das potyfm Stpmflricki&amp;s mW Tncbrmfla spiraHs FasdfcUa hqpafeca Schistosoma mafhcmi Lspromatous leprosy StmptocQcais pfisumon/a^e Haemophikts tnflumnza P&amp;wdomQims amugmcha\n1\tSee Fabris and Mocchegiani (1995J.\n2\tSee Shankar and Prasad (1990).\nExtra\u00edda de Mocchegiani e Muzzioli, 2000.\n23\nTABLE 2\nExmiptes of diseases ar\u00bb conditions where zinc deficiency cm ater host fense capac%\nSubjects\tZinc status\tImmune parameter^\nSckle Cell Anemia 1\t90 ydL-\tNK4 function 5094 normal\n28 yr old\twhere 115\tDecreased IL-2\nsubjects\tftgydL was nonnal\tAnergic DTH4 28% increase in unnaiy infections\nSngle adult3 Gl dissrdsr Prolonged TPM*\t40#gZn/dL\t40% iymptiocytes 30% Th 1Q% NK activity 49% mitogen response\nElderlyi\t1Q8 ftg ZrV dL\tDecreased numbers of neutrephiis and lymphacytas and decreased 1-2 production\nAIDS\u00bb\tMarginally zincdefident ancda Se-defident\tRsduced T helper cells Reduced antibody mediated responses Reduced call mediated responses Increased infection and morbidity\n1 Kaplan et al. 1988.\n3\tAllan et al. 1983.\n3 Baum et al. 1995.\nAbbreviations used: AIDS, acquired immunodeficiency syndroms: DTH, delt^ed type hypersensitivity: Gl. gastrointestinal; nK. natural killer calls: TPN, total parenteral nutrition; IL, interleukin.\nExtra\u00edda de Fraker et al., 2000.\n24\nTABLE 2\nEffect of zfnc-arf&amp;jiMts dtet and supptementsrion with zinc on frequency of infectious episodes in infected experimental! a/Umsfs arx m various congenital and acqulTed diaeesss or conditions In tomans,\nPathogens in experimental animals\tReduction (%)\tRefisrance\tDisease or condition in humans\tReauction m>)\tRtferancs\nGend'ida albicans (mica)\t3S\tSavin st al. 199?. Singh et aK 12192\tDown's syndrome\t50\tLicasiro et al. 1994\nPlasmodium ycxTa (mice)\t30\tShankar et all 199S\tMalnutrition\t2S\tCastillo-Duran at al. 1987\nTrypnasans cmsi (mice)\t35\tFratoer et al. 1982\tAcrodermatitis enieropathica\t28\tChandra. 1980\nToxoplasma gondii (mica)\t40\tTasci et al. 1995\tCongenital herpes (herpes smpex II)\t50\tJones 1979\nTrictmoXa spiralis (rat)\t40\tFenwick et al. 1990\tLeprosy Malaria Chronic diarrhea Acute lower respiratory infection Buma\t40 as 20 25 SO\tMathuu etal. 1984 Shankar et al. 11\u00ae 7 Sazawal et al. 1995, Ruel etal. 1997 Sazmal et al. 1998 Berger et al. 1998\nThe zinc-adequate diet in experimented animals was carried out for 2-3 mo. Supplementation with zinc in humans was carried out for 1-2 mo at physiological dose (USDA 1976). Ths data for percent reduction in experimental animals was obtained 2 months before and at the end of zinc-adequate diet. The data for humans was obtainad 6 mo or 1 y before and 6 mo or 1y after zinc supplementation.\nExtra\u00edda de Mocchegiani e Muzzioli, 2000.\n25\nIN VITRO ZINC SUPPLEMENTATION OF HUMAN MACROPHAGES INFECTED WITH DIFFERENT LEISHMANIA SPECIES STRONGLY REDUCES INTRACELLULAR PARASITE LOAD\nSantana G., Bahia C., Silva M.P., B\u00e1flca A., Barral-Netto M. &amp; Van Weyenbergh J.\nLIMI - Centro de Pesquisas Gon\u00e7alo Moniz - Funda\u00e7\u00e3o Oswaldo Cruz, Salvador-BA, Brasil.\nIn spite of the large amount of literature dedicated to the importance of zinc to the immune response in vitro and in vivo in numerous infectious and non-infectious diseases, no data exist on the possible role of zinc (Zn\"\") in leishmaniasis. However, a recent publication describes low serum zinc and iron levels in cutaneous leishmaniasis patients in Turkey (Kocjngit et al., 1998). This zinc deficiency in patients with active disease is of significant interest, considering that zinc is essential to the functioning of cellular immunity, which correlates to resistance and cure in human as well as experimental murine leishmaniasis, while humoral immunity does not. Therefore, we were interested in a possible effect of zinc supplementation in vitro on the immune capacity of human macrophages infected with different Leishmania species.\nOur results show that addition of zinc (as ZnCb) to macrophages infected with L. amazonensis dramatically decreased intracellular parasite load. This leishmanicidal effect of zinc was already observed at 24 h of treatment and gradually increased with time. Reduction in parasite load was maximal at 10 pM of Zn\"' and decreased at 30 |iM, while there was no significant effect at 100 |iM. Similar results were obtained with macrophages infected with L. braziliensis or L. major, indicating that the action of zinc was not species-specific. Zn\"\" at 10 or 30 jiM slowed down proliferation of axenically grown L. amazonensis promastigotes, but did not have an overt cytotoxic effect, suggesting that the observed leishmanicidal effect of zinc is mediated by the host cell. The molecular mechanism through which zinc reduces intracellular parasite burden is currently under investigation.\nXXV Annual Meeting on Basic Research in Chagas Disease XIV Meeting of Brazilian Society of\nProtozoology, Mem. Inst. Oswaldo Cruz, 93: 255, Suppl. II, 1998.\n26"}]}}}